Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000

Breunis Willemijn B, Tarazona-Santos Eduardo, Chen Renee, Kiley Maureen, Rosenberg Steven A, Chanock Stephen J

Abstract excerpt

Blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a down-regulator of T-cell activation, can cause cancer regression in patients with metastatic melanoma. However, not all patients respond well to the therapy and some develop severe autoimmune reactions. We hypothesized that c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antigens, CD
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA4 gene

Share to Haplotypes

Share to Ipilimumab

Share to Melanoma

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 18528295
DOI: 10.1097/CJI.0b013e31817fd8f3
PMCID: PMC3276400

Genes

CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18528295-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.PMID 18528295Read ↗

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.Semantic proximity Read ↗

CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma.Semantic proximity Read ↗

Association of Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Genetic Variants with Risk and Outcome of Cutaneous Melanoma.Semantic proximity Read ↗

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Semantic proximity Read ↗

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Semantic proximity Read ↗

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.Semantic proximity Read ↗

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudySemantic proximity Read ↗

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapySemantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma.Semantic proximity Read ↗

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.Semantic proximity Read ↗

Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.